# Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers

> **NCT02907294** · PHASE1 · TERMINATED · sponsor: **Palobiofarma SL** · enrollment: 8 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** PBF-999 / 160 mg
- **DRUG:** PBF-999 / 320 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02907294
- **Lead sponsor:** Palobiofarma SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2016-04
- **Final completion:** 2016-05
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** change in the therapeutic indication
- **Last updated:** 2016-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02907294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02907294, "Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02907294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*